Department of Hepatology, Toranomon Hospital, Tokyo, Japan. akuta-gi @ umin.ac.jp
Intervirology. 2010;53(3):188-92. doi: 10.1159/000289343. Epub 2010 Mar 3.
In treatment-resistant patients with genotype 2 chronic hepatitis C the suitable treatment duration is still unclear. The aims were to investigate extending combination therapy with peginterferon plus ribavirin for genotype 2.
7 patients infected with genotype 2 at a high viral load and who did not achieve a sustained virological response (SVR) with the first course of 24-week IFN plus ribavirin were recruited into the study protocol with a total of 48 weeks of peginterferon plus ribavirin therapy.
SVR was achieved in 5 of 7 patients (71%). All 4 patients (100%) who were in relapse with the first course achieved SVR. Only 1 of 3 patients (33%) who had a non-virological response (NVR) with the first course achieved SVR. All 4 patients who had an early virological response (EVR) with the first course achieved EVR and SVR. Two of 3 patients who had no EVR with the first course also did not achieve EVR and SVR. One patient who had no EVR or a NVR during the first course achieved EVR and SVR with the second course.
Our results suggest that extending combination therapy for genotype 2 chronic hepatitis C might be useful for patients who relapse following 24-week combination therapy.
对于基因型 2 慢性丙型肝炎的治疗抵抗患者，合适的治疗持续时间仍不清楚。本研究旨在探讨延长聚乙二醇干扰素联合利巴韦林治疗基因型 2 的方案。
7 例基因型 2 高病毒载量且首次接受 24 周 IFN 联合利巴韦林治疗未能获得持续病毒学应答（SVR）的患者，纳入该研究方案，接受总共 48 周的聚乙二醇干扰素联合利巴韦林治疗。
7 例患者中有 5 例（71%）获得 SVR。首次疗程复发的 4 例患者（100%）均获得 SVR。首次疗程无病毒学应答（NVR）的 3 例患者中仅 1 例（33%）获得 SVR。首次疗程有早期病毒学应答（EVR）的 4 例患者均获得 EVR 和 SVR。首次疗程无 EVR 的 3 例患者中，有 2 例也未获得 EVR 和 SVR。首次疗程无 EVR 或 NVR 的 1 例患者在第二疗程中获得 EVR 和 SVR。
我们的结果表明，对于首次 24 周联合治疗后复发的基因型 2 慢性丙型肝炎患者，延长联合治疗可能是有用的。
